Allarity Therapeutics Inc (ALLR)

[INV4]

Allarity Therapeutics (ALLR) Price Target Increased by 80.00% to $9.18

2025-08-06

The average one-year price target for Allarity Therapeutics (NasdaqCM:ALLR) has been revised to $9.18 / share. This is an increase of 80.00% from the prior estimate of $5.10 dated December 22, 2022.

The price target is an average of many targets provided by analysts. The latest targets range from a low of $9.09 to a high of $9.45 / share. The average price target represents an increase of 783.54% from the latest reported closing price of $1.04 / share.

What is the Fund Sentiment?
There are 12 funds or institutions reporting positions in Allarity Therapeutics. This is an increase of 3 owner(s) or 33.33% in the last quarter. Average portfolio weight of all funds dedicated to ALLR is 0.00%, an increase of 93.86%. Total shares owned by institutions increased in the last three months by 9.77% to 126K shares.

What are Other Shareholders Doing?
Geode Capital Management holds 34K shares representing 0.22% ownership of the company.

FSMAX - Fidelity Extended Market Index Fund holds 27K shares representing 0.18% ownership of the company. In its prior filing, the firm reported owning 7K shares , representing an increase of 73.70%. The firm increased its portfolio allocation in ALLR by 332.40% over the last quarter.

Corsair Capital Management holds 20K shares representing 0.13% ownership of the company.

Barclays holds 10K shares representing 0.07% ownership of the company.

FCFMX - Fidelity Series Total Market Index Fund holds 7K shares representing 0.04% ownership of the company. In its prior filing, the firm reported owning 3K shares , representing an increase of 50.94%. The firm increased its portfolio allocation in ALLR by 105.60% over the last quarter.

https://fintel.io/news/allarity-therapeutics-allr-price-target-increased-by-8000-to-918-496

(Targets are not always met)

$ALLR